Company Profile

  1. You are here:    Home
  2. Search Databases
  3. Search Company Registry
  4. Company Profile

GlycoPath LLC
Profile last edited on: 3/8/2023      CAGE: 89Q46      UEI: QL7NPDFW6B47

Business Identifier: Innovative solutions to roadblocks in biomarker discovery and clinical assay development
Year Founded
2019
First Award
2019
Latest Award
2022
Program Status
Active
Popularity Index

Edit Company Profile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
  Explanation Edit

Location Information

4058 Blackmoor Street
Mount Pleasant, SC 29466
   (214) 748-3647
   sales@glycopath.com
   www.glycopath.com
Location: Single
Congr. District: 01
County: Charleston

Public Profile

Focused on biomarker research, GlycoPath had been reported as addressing the development of new applications utilizing MALDI Mass Spectrometry Imaging to study changes in the glycosylation of various disease states. For some time it had been understood that alterations in glycosylation are associated with development and progression of many types of chronic and acute diseases. The effort of the GlycoPath LLC team had been to accomplish development of accurate simplified assays - effectively streamlining methods having proven clinical impact - that would offer the potential of improved patient care and treatment.

Extent of SBIR involvement

User Avatar
Phase I Awards
2
Phase II Awards
0
Conversion Rate
0.00%
Phase I Dollars
$651,498
Phase II Dollars
$0
Total Awarded
$651,498

Synopsis: Awardee Business Condition

Employee Range
1-4
Revenue Range
Less than .5M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects
Year Phase Agency Total Amount
2022 1 NIH $428,443
Project Title: Development of the GlycoHCCTyper for the early detection of HCC
2019 1 NIH $223,055
Project Title: Development of the Glycofibrotyper for Detection of Liver Fibrosis
0 1 NIH $275,397
Project Title: Glycan biomarker panels in liquid biopsies for predicting treatment response in lupus nephritis

Key People / Management

  Kathy Phlegar -- Chief Executive Officer

  Peggi M Angel -- Founder and Chief Scientific Officer

  Stephen Castellino -- Chief Scientific Officer

  Richard R Drake -- Founder & Advisor

  Anand S Mehta -- Chief Financial Officer

  Danielle Scott -- Chief Officer of Product Devlopment

Company News

There are no news available.